Filters
Psychedelics
MIRA Pharmaceuticals Is Solving Neuropathic Pain With Ketamine
MIRA Pharmaceuticals (NASDAQ: MIRA) has announced new pre clinical data validating that their novel oral ketamine analogue has shown efficacy reducing pain.
August 27, 2024
Biotech
Psychedelics
Regulatory
Psychedelics
Google's Co-Founder Is Backing A Psychedelic Startup
Google (NASDAQ:GOOG) co-founder Sergey Brin has backed psychedelic medicine startup Soneira with a $15 million investment to advance their ibogaine research.
July 22, 2024
Psychedelics
Biotech
Venture Capital
Psychedelics
Optimi Health Is Now Legally Producing MDMA and Psilocybin Capsules
Optimi Health (CSE:OPTI) has been awarded a Drug Establishment License from Health Canada to manufacture and sell psilocybin and MDMA capsules.
June 3, 2024
Biotech
Psychedelics
Public Companies
Regulatory
Psychedelics
Big Pharma Is Making Another Move Into Psychedelic Drug Development
Pharmaceutical giant AbbVie (NYSE: ABBV) has announced a new partnership with psychedelic drug developer Gilgamesh Pharmaceuticals to develop psychedelic drugs.
May 13, 2024
Biotech
Public Companies
Psychedelics
Compass Pathways Is On The Verge Of Another Psychedelic Breakthrough
Psychedelic drug developer Compass Pathways (NASDAQ:CMPS) has announced early clinical validation for their novel synthetic psilocybin compound.
May 9, 2024
Biotech
Psychedelics
Public Companies
Regulatory
Psychedelics
Psychedelics Are On The Verge Of Creating A Biotech Revolution
Psychedelic drug developers have been on a rapid rise, with multiple new Breakthrough Therapy designations from the FDA and significant venture capital raises.
March 21, 2024
Biotech
Psychedelics
Public Companies
Regulatory
Venture Capital
Psychedelics
Gilgamesh Lands Government Grant To Solve Opioid Addiction
Gilgamesh has received a $14 million grant from the National Institute on Drug Abuse to advance the clinical development of their novel cardiac-safe ibogaine.
March 16, 2024
Biotech
Regulatory
Startups
Psychedelics
Psychedelic Depression Drug Lands Breakthrough Therapy Designation From The FDA
Cybin (NYSE: CYBN) has been granted a Breakthrough Therapy designation from the FDA for their novel psychedelic molecule CYB003 for Major Depressive Disorder.
March 14, 2024
Psychedelics
Public Companies
Biotech
Discover the world's most disruptive early stage companies with 35,000+ investors.
The markets and trends that matter, made simple.
Join top talent at the world's most respected institutions, companies, and venture capital funds.